INTERPACE DIAGNOSTICS ANNOUNCES PARTICIPATION AT THE 20TH ANNUAL GLOBAL INVESTMENT CONFERENCE SPONSORED BY H.C.WAINWRIGHT & C...
August 27 2018 - 8:30AM
Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) (“Interpace”
or “the Company”), a fully integrated commercial and bioinformatics
company that provides clinically useful molecular diagnostic tests
and pathology services for improved patient diagnosis and
management, today announced that the Company will present at the
upcoming Rodman & Renshaw 20th Annual Global Investment
Conference, sponsored by H.C. Wainwright & Co., being
held on September 4-6, 2018 at the St. Regis New York Hotel in
New York City. Jack Stover, President and CEO of Interpace, will
provide an overview of the business and will be available to
participate in one-on-one meetings with investors who are
registered to attend the conference.
Presentation Details:
Date: Thursday, September 6,
2018Time: 2:10 – 2:35 pm
ETLocation: Louis XVI A (2nd Floor) at the St.
Regis Hotel in New York City
The presentation will be webcast live. To access
the webcast, please visit www.rodmanevents.com. The webcast replay
will remain available for 90 days following the live
presentation.
About Interpace Diagnostics Group,
Inc.Interpace is a fully integrated commercial and
bioinformatics company that provides clinically useful molecular
and related first line diagnostic tests and pathology services for
evaluating risk of cancer by leveraging the latest technology in
personalized medicine for improved patient diagnosis and
management. The Company currently has four commercialized molecular
tests and one test in a clinical evaluation process (CEP);
PancraGEN® for the diagnosis and prognosis of pancreatic cancer
from pancreatic cysts; ThyGenX® (currently ThyGeNEXT™) for the
diagnosis of thyroid cancer from thyroid nodules utilizing a next
generation sequencing assay; ThyraMIR® for the diagnosis of thyroid
cancer from thyroid nodules utilizing a proprietary gene expression
assay; and RespriDx™, that differentiates lung cancer of primary
vs. metastatic origin. BarreGEN®, for Barrett's Esophagus, is
currently being “soft launched” with key opinion leaders as we
continue to gather data on this assay that will assist us in
seeking favorable reimbursement as well as important clinical
information. Barrett's Esophagus is a rapidly growing diagnosis
that affects over three million people in the US, and over time can
progress to esophageal cancer. The Company’s data base includes
data from over 45,000 patients who have been tested using the
Company’s current products, including over 15,000 molecular tests
for thyroid nodules. Interpace has been designated by CIO
Applications magazine as one of the top 20 companies for providing
bioinformatics solutions. Interpace’s mission is to provide
personalized medicine through molecular diagnostics, innovation and
data to advance patient care based on rigorous science. For more
information, please visit Interpace’s website at
www.interpacediagnostics.com
Forward Looking
StatementsThis press release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, Section 21E of the Securities Exchange Act
of 1934 and the Private Securities Litigation Reform Act of 1995,
relating to the Company's future financial and operating
performance, competitive and market conditions and future business
decisions, all of which are difficult or impossible to predict
accurately and many of which are beyond the Company's control.
These statements also involve known and unknown risks,
uncertainties and other factors that may cause the Company's actual
results to be materially different from those expressed or implied
by any forward-looking statement. Known and unknown risks,
uncertainties and other factors include, but are not limited to,
the Company’s history of losses, the Company's ability to
adequately finance the business, the market's acceptance of its
molecular diagnostic tests, its ability to retain or secure
reimbursement, its ability to secure additional business and
generate higher profit margins through sales of its molecular
diagnostic tests, in-licensing or other means, projections of
future revenues, growth, gross profit and anticipated internal rate
of return on investments and its ability to maintain its NASDAQ
listing. Additionally, all forward-looking statements are subject
to the “Risk Factors” detailed from time to time in the Company's
SEC filings, including its Annual Report on Form 10-K for the
fiscal year ended December 31, 2017, filed on March 23, 2018,
Quarterly Reports on Form 10-Q and other SEC filings. Because of
these and other risks, uncertainties and assumptions, undue
reliance should not be placed on these forward-looking statements.
In addition, these statements speak only as of the date of this
press release and, except as may be required by law, the Company
undertakes no obligation to revise or update publicly any
forward-looking statements for any reason.
CONTACTS:
Interpace Diagnostics
Investor Relations
Joseph Green / Andrew Gibson
646-653-7030 / 7719
jgreen@edisongroup.com/ agibson@edisongroup.com
Interpace Biosciences (NASDAQ:IDXG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Interpace Biosciences (NASDAQ:IDXG)
Historical Stock Chart
From Sep 2023 to Sep 2024